Select a category to find the resources you need.

All Resources

{{item.DisplayName}}

Filter by:

{{MainSelectedItem.DisplayName}}

Clear

{{displayitem.DisplayName}}

{{sample.language}}

EmailEmail

{{sample.language}}

PlayPlay

EmailEmail

Clear

Email Share

To share your selected resources please fill out the information below.

Please enter a valid recipient email address
Please enter your name
Please enter a valid email address

Support for the reimbursement process.
Reimbursement Support

Get information about navigating the
reimbursement process. Find enrollment forms, learn about PA assistance, and more.

Product support for EYLEA® (aflibercept) Injection.
Product Support

Find complete product support—
guiding you through
orders, returns, and more.

EYLEA news, events, and more.
About EYLEA

See how EYLEA is backed
by 8 pivotal clinical studies.

See More Important Safety Information and Indications
  • CONTRAINDICATIONS: EYLEA is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.